Peijia Medical Ltd. has announced its unaudited operating statistics for the year ended December 31, 2025. The company reported revenue of approximately RMB 700.0–720.0 million for 2025, representing an increase of around 13.7% to 17.0% compared to RMB 615.5 million in 2024. The revenue growth was primarily attributed to strong performance across all three product lines of the neurointerventional business and ongoing market share expansion in China's transcatheter aortic valve regurgitation market. The figures are preliminary and unaudited, and the company expects to publish its full annual results in March 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company's shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peijia Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12017301), on February 05, 2026, and is solely responsible for the information contained therein.